Friday 6 November 2026 Export UPC’s income statement to Excel — free account

Universe Pharmaceuticals INC

UPC Healthcare Drug Manufacturers Specialty & Generic

Universe Pharmaceuticals INC’s revenue for fiscal 2025 (year ended September 2025) was $17.9 million, down 22.4% from fiscal 2024.

1.35 0.05 −3.57%

Follow UPC

Alert me

Market cap: $7.0M
P/E: 0.0×
Fwd P/E: 4.1×
Dividend yield: —
F-score: 4/9
Altman Z: 0.63
Beneish M: −2.56
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 97.52%

Capital & Financial Ratios $m

Size

Market Cap 7.04

Revenue ttm 82.30

Net income ttm (17.24)

Free cash flow ttm (17.21)

Net debt Q (19.50)

Valuation

P/E 0.00

Forward P/E 4.14

Price / sales 0.00

Forward P/S Powerpack

Price / FCF 0.00

Price / book 0.00

Financial health

Current ratio Q 4.05

Debt / equity Q 0.17

Interest coverage Q —

Growth

Revenue growth Q −23.98%

Operating income growth Q —

EPS, this year —

EPS, next year A —

Revenue, next year A −16.43%

EPS, past 5 yrs —

EPS, next 5 yrs A —

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

EV/FCF against its own 10 years 26.92%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	5	29	34	29
Receivables	13	19	15	22
Inventory	3	2	2	2
Other	4	1	2	2
	25	52	54	55

	2023	2024	2025	Q'26
Payables	5	5	2	4
ST’ Debt	5	6	9	7
Other	—	—	0	0
	14	20	13	14

Compound Annual Growth %

	10y	5y	3y
Sales	—	(10.27%)	(23.66%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	21.96%	6.52%

EPS $

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	(8.06)
’24	—	—	—	—	(626.96)
’23	—	—	—	—	(1.09k)
’22	—	—	—	—	(1.44k)
’21	—	—	—	—	2.16k
’20	—	—	—	—	1.70k

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	18
’24	—	—	—	—	23
’23	—	—	—	—	32
’22	—	—	—	—	40
’21	—	—	—	—	48
’20	—	—	—	—	31

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	(5)
’24	—	—	—	—	(10)
’23	—	—	—	—	1
’22	—	—	—	—	(1)
’21	—	—	—	—	(2)
’20	—	—	—	—	6

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(5)	—	—	—	—
’25	2	—	(5)	—	(5)
’24	(2)	—	(10)	—	(10)
’23	5	—	1	—	1
’22	6	—	(1)	—	(1)
’21	1	—	(13)	—	(13)
’20	—	—	6	—	6

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Mar ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	—	—	33	33	31	48	40	32	23	18	82		(8.5%)	—	—	—	—
	Gross margin, %	—	—	40.35	40.35	45.90	52.78	54.53	31.93	26.37	35.28	49.77		(5.1) pt	Powerpack Universe Pharmaceuticals INC’s next three years, line by line See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	—	—	10	(3)	10	14	(8)	(4)	(8)	(4)	(4)		n/m
	EBT margin, %	—	—	29.05	0.00	32.90	28.51	(19.89)	(13.39)	(35.27)	(20.56)	(4.43)		(49.6) pt
	Net income	—	0	0	0	8	11	(9)	(7)	(9)	(4)	(17)		n/m
Per share, $
Per share, $	Revenue	—	—	0.00	7,552.11	6,978.18	9,053.21	6,690.53	5,384.78	1,656.44	39.17	0.00		n/m
	Earnings	—	—	2.07	1,697.89	1,699.41	2,158.49	(1,438.99)	(1,089.21)	(626.96)	(8.06)	(1.46)		n/m
	Cash flow	—	—	1.21	3,000.86	1,389.82	(387.89)	(218.72)	186.13	(683.94)	(11.08)	0.00		n/m
	Capex	—	—	0.00	(19.55)	(11.77)	(2,089.36)	(15.53)	(7.37)	(25.99)	(0.75)	0.00		n/m
	Free cash flow	—	—	1.21	2,981.32	1,378.05	(2,477.25)	(234.25)	178.77	(709.93)	(11.83)	0.00		n/m
	Book value	—	—	0.00	2,814.57	4,727.93	11,119.70	7,740.38	4,661.70	3,273.59	123.12	0.00		n/m
	Shares, m	—	—	4	0	0	0	0	0	0	0	—		(25.8%)
Valuation, ×
Valuation, ×	P/E	—	—	4.66	4.66	4.66	2,864.59	2,864.59	0.00	0.00	0.00	0.00		717.9
	P/S	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		0.0
	P/B	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		0.0
	EV/Sales	—	—	0.00	0.00	0.00	0.00	(0.17)	0.00	(0.26)	(0.27)	(0.24)		(0.1)
	EV/FCF	—	—	0.00	0.00	0.00	(0.95)	2.00	0.02	3.37	1.47	1.13		0.7
Cash, $m
Cash, $m	Operating cash flow	—	—	4	13	6	(2)	(1)	1	(10)	(5)	(16)		n/m
	Capex	—	—	0	0	0	(11)	0	0	0	0	(1)		+13.0%
	Free cash flow	—	—	4	13	6	(13)	(1)	1	(10)	(5)	(17)		n/m
Balance, $m
Balance, $m	Working capital	—	—	7	11	15	39	28	12	31	40	42		+29.1%
	Net debt	—	—	(3)	(1)	(7)	(17)	(15)	0	(22)	(24)	(19)		+33.8%
	Shareholders’ equity	—	—	12	12	21	59	46	28	46	56	56		+24.1%
Returns, %
Returns, %	ROA	—	—	42.34	52.65	38.10	22.88	(13.47)	(13.00)	(15.91)	(5.35)	0.00		(47.7) pt
	ROIC	—	—	70.41	0.00	47.85	20.48	(14.75)	(8.80)	(20.89)	(5.73)	0.00		(76.1) pt
	ROE	—	—	122.18	0.00	45.55	28.39	(16.58)	(17.69)	(23.76)	(7.23)	0.00		(129.4) pt
People
People	Employees	—	—	—	—	169	263	224	225	225	216	—		+5.0%
	Revenue/emp, $m	—	—	0.00	0.00	0.18	0.18	0.18	0.14	0.10	0.08	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Sep 2025 · latest quarter Jan 0001 · fundamentals updated 25 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
OPTH Optimi Health Corp.	$13.7M	—	—	—	n/m	—	89.93%	(1,364.28%)	Compare
BFRI Biofrontera Inc.	$12.0M	— (loss-making)	— (loss-making)	+32.92% (above 0%: growing)	n/m	+45.57% (above 0%: growing)	79.92%	(4.37%)	Compare
INM InMed Pharmaceuticals Inc.	$7.3M	— (loss-making)	—	−26.22% (below 0%: shrinking)	n/m	+40.84% (above 0%: growing)	22.46%	0.00%	Compare
UPC Universe Pharmaceuticals INC	$7.0M	— (loss-making)	4.1×	−23.98% (below 0%: shrinking)	−110.15% (below 0%: shrinking)	−84.99% (below 0%: shrinking)	32.57%	0.00%
SNOA Sonoma Pharmaceuticals, Inc.	$5.1M	— (loss-making)	— (loss-making)	+59.55% (above 0%: growing)	n/m	+69.31% (above 0%: growing)	40.23%	(0.62%)	Compare
GELS Gelteq Limited	$4.9M	—	—	—	—	−40.15% (below 0%: shrinking)	—	—	Compare
YCBD cbdMD, Inc.	$4.4M	— (loss-making)	— (loss-making)	+20.55% (above 0%: growing)	n/m	+34.80% (above 0%: growing)	54.69%	(20.36%)	Compare
APUS Apimeds Pharmaceuticals US, Inc.	$4.1M	— (loss-making)	—	—	n/m	−67.94% (below 0%: shrinking)	—	0.00%	Compare
RDHL Redhill Biopharma Ltd.	$3.8M	— (loss-making)	— (loss-making)	−90.32% (below 0%: shrinking)	n/m	−107.31% (below 0%: shrinking)	(7.52%)	0.00%	Compare
Median of peers	$5.0M	—	—	+20.55%	—	+34.80%	47.46%	(0.62%)

All 84 Drug Manufacturers Specialty & Generic stocks →